Liquid Biopsies – Products

Beckman Coulter Life Sciences will have a full team of dedicated professionals and informative programming at the upcoming Society for Laboratory Automation and Screening International Conference and Exhibition.

Only a small amount of cell-free DNA (cfDNA) can be found in circulation, therefore efficient and highly sensitive technologies such as next-generation sequencing (NGS) are typically being used to detect this biomarker.

Thermo Fisher Scientific has introduced over 50 new Absolute Q Liquid Biopsy Assays to run on the Applied Biosystems QuantStudio Absolute Q dPCR System.

Personalis has announced a collaboration with UC San Francisco that will deploy a personalized liquid biopsy-based research use only assay for a study of patients with colorectal cancer.

Beckman Coulter Life Sciences announces its continuing commitment to the next generation of researchers and scientists with a call for registrations for its SPRI Grants for Genomic Research.

The Twist NGS Methylation Detection System provides a robust, end-to-end sample preparation solution for identifying methylated regions in the human genome. This system offers the most efficient methylation detection available.

When it comes to cancer, diagnosis often relies on tissue biopsy in conjunction with medical imaging. In addition to sometimes being inconclusive, tissue biopsies are associated with risks, high costs and inconvenience for patients, making them ill-suited for screening or tracking disease progression.

Yourgene Health plc announces today the launch of the LightBench® Detect, the latest addition to its Ranger® Technology instrumentation portfolio at the 26th International Conference on Prenatal Diagnosis and Therapy.

Biotech Support Group and Leiden University Medical Center announce publication of a journal article based upon on their joint goal to correlate BSG’s patent pending Stroma Liquid Biopsy™ panel of blood-borne biomarkers, to tissue derived tumor-stroma ratio scoring methods.

Liquid biopsies are rapidly gaining traction and becoming a standard of care for cancer. They are an attractive alternative to invasive, painful, costly tissue biopsies and can facilitate real-time monitoring while providing insight into the disease state, even for tissues that are difficult to access, such as brain cancers.